LP-261

• Description :

  LP-261 is a potent and orally active anti-mitotic agent and shows an inhibition of in vitro tubulin polymerization with an EC50 of 3.2 μM[1]. LP-261 inhibits growth of a human non-small-cell lung tumor (NCI-H522) in vivo and can be used for cancer research[1].

• UNSPSC :

  12352005

• Target :

  Microtubule/Tubulin

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/lp-261.html

• Purity :

  99.94

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles :

  CS(=O)(NC1=CC(C(C2=CC(OC)=NC=C2)=O)=CC(C3=CC=CC4=C3C=CN4)=C1)=O

• Molecular Formula :

  C22H19N3O4S

• Molecular Weight :

  421.47

• References & Citations :

  [1]Rupa S Shetty, et al. Synthesis and pharmacological evaluation of N- (3- (1H-indol-4-yl) -5- (2-methoxyisonicotinoyl) phenyl) methanesulfonamide (LP-261), a potent antimitotic agent. J Med Chem. 2011 Jan 13;54 (1) :179-200

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [915412-67-8]